1-14 of 14
Uwe Rix
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract C054: PARP16 modulates MYC expression and susceptibility of Ewing’s Sarcoma cells to PARP1 inhibition

Ou Deng, Xueli Li, Vinayak C Palve, Bin Fang, Damon R Reed, Uwe Rix
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): C054.
https://doi.org/10.1158/1535-7163.TARG-23-C054
Published: 01 December 2023
View article titled, Abstract C054: PARP16 modulates MYC expression and susceptibility of Ewing’s Sarcoma cells to PARP1 inhibition
Journal Articles

Abstract P018: Integrative proteomics of PARP1 protein complexes and post-translational modifications implicates DDR and AKT-mTOR signaling in mediating response or primary resistance of ovarian carcinoma cells to PARP1 inhibitors

Ou Deng, Sweta Dash, Thales Nepomuceno, Bin Fang, Douglas Marchion, John Koomen, Alvaro N. Monteiro, Uwe Rix
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P018.
https://doi.org/10.1158/1535-7163.TARG-21-P018
Published: 01 December 2021
View article titled, Abstract P018: Integrative proteomics of PARP1 protein complexes and post-translational modifications implicates DDR and AKT-mTOR signaling in mediating response or primary resistance of ovarian carcinoma cells to PARP1 inhibitors
Journal Articles

Abstract B022: PARP1 complex composition as a predictor of response to PARP inhibitors in BRCA-linked ovarian carcinoma

Ou Deng, Sweta Dash, Thales Nepomuceno, Ming D Han, Bin Fang, Doug Marchion, Alvaro N Monteiro, Uwe Rix
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): B022.
https://doi.org/10.1158/1535-7163.TARG-19-B022
Published: 01 December 2019
View article titled, Abstract B022: PARP1 complex composition as a predictor of response to PARP inhibitors in BRCA-linked ovarian carcinoma
Journal Articles

Abstract B021: PARP16 is a novel target of talazoparib which contributes to synergy with adavosertib in SCLC

Vinayak Palve, Clare Knezevic, Yunting Luo, Xueli Li, Slivia Novakova, Eric Welsh, Bin Fang, Fumi Kinose, Eric B Haura, Alvaro N Monteiro, John M Koomen, Harshani R Lawrence, Uwe Rix
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): B021.
https://doi.org/10.1158/1535-7163.TARG-19-B021
Published: 01 December 2019
View article titled, Abstract B021: PARP16 is a novel target of talazoparib which contributes to synergy with adavosertib in SCLC
Journal Articles

Abstract C110: Cancer associated fibroblast-derived IGF-binding proteins augment osimertinib activity in EGFR-mutant NSCLC cells

Lily L. Remsing Rix, Natalia J. Sumi, Annamarie T. Bryant, Xueli Li, Eric A. Welsh, Bin Fang, Brent M. Kuenzi, Scott J. Antonia, Andriy Marusyk, Christine M. Lovly, John M. Koomen, Eric B. Haura, Uwe Rix
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): C110.
https://doi.org/10.1158/1535-7163.TARG-19-C110
Published: 01 December 2019
View article titled, Abstract C110: Cancer associated fibroblast-derived IGF-binding proteins augment osimertinib activity in EGFR-mutant NSCLC cells
Journal Articles

Abstract C114: Cancer cell induced activation of associated fibroblasts is PDGFR-mediated

Anurima Majumder, Martial Boutchueng-Djidjou, Jae-Young Kim, Natalia Sumi, Uwe Rix, Eric B Haura
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): C114.
https://doi.org/10.1158/1535-7163.TARG-19-C114
Published: 01 December 2019
View article titled, Abstract C114: Cancer cell induced activation of associated fibroblasts is PDGFR-mediated
Journal Articles

Abstract B072: MEK inhibition modulates cytokine response to mediate therapeutic efficacy in lung cancer

Mengyu Xie, Hong Zheng, Ranjna Madan-Lala, Wenjie Dai, Nicholas T. Gimbrone, Zhihua Chen, Fumi Kinose, Sarah A. Blackstone, Keiran S. M. Smalley, Douglas Cress, Eric B. Haura, Uwe Rix, Amer A. Beg
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): B072.
https://doi.org/10.1158/1535-7163.TARG-19-B072
Published: 01 December 2019
View article titled, Abstract B072: MEK inhibition modulates cytokine response to mediate therapeutic efficacy in lung cancer
Journal Articles

Targeting the BRD4-HOXB13 Coregulated Transcriptional Networks with Bromodomain-Kinase Inhibitors to Suppress Metastatic Castration-Resistant Prostate Cancer

Niveditha Nerlakanti, Jiqiang Yao, Duy T. Nguyen, Ami K. Patel, Alexey M. Eroshkin, Harshani R. Lawrence, Muhammad Ayaz, Brent M. Kuenzi, Neha Agarwal, Yunyun Chen, Steven Gunawan, Rezaul M. Karim, Norbert Berndt, John Puskas, Anthony M. Magliocco, Domenico Coppola, Jasreman Dhillon, Jingsong Zhang, Subramaniam Shymalagovindarajan, Uwe Rix, Youngchul Kim, Ranjan Perera, Nicholas J. Lawrence, Ernst Schonbrunn, Kiran Mahajan
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (12): 2796–2810.
https://doi.org/10.1158/1535-7163.MCT-18-0602
Published: 03 December 2018
View article titled, Targeting the BRD4-HOXB13 Coregulated Transcriptional Networks with Bromodomain-Kinase Inhibitors to Suppress Metastatic Castration-Resistant Prostate Cancer
Open the PDF for Targeting the BRD4-HOXB13 Coregulated Transcriptional Networks with Bromodomain-Kinase Inhibitors to Suppress Metastatic Castration-Resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Ceritinib Enhances the Efficacy of Trametinib in BRAF/NRAS-Wild-Type Melanoma Cell Lines

Daniel Verduzco, Brent M. Kuenzi, Fumi Kinose, Vernon K. Sondak, Zeynep Eroglu, Uwe Rix, Keiran S.M. Smalley
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1): 73–83.
https://doi.org/10.1158/1535-7163.MCT-17-0196
Published: 01 January 2018
View article titled, Ceritinib Enhances the Efficacy of Trametinib in <em>BRAF/NRAS</em>-Wild-Type Melanoma Cell Lines
Open the PDF for Ceritinib Enhances the Efficacy of Trametinib in <em>BRAF/NRAS</em>-Wild-Type Melanoma Cell Lines in another window
Includes: Supplementary data
Journal Articles

PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer

Ankita Jhuraney, Nicholas T. Woods, Gabriela Wright, Lily Rix, Fumi Kinose, Jodi L. Kroeger, Elizabeth Remily-Wood, W. Douglas Cress, John M. Koomen, Stephen G. Brantley, Jhanelle E. Gray, Eric B. Haura, Uwe Rix, Alvaro N. Monteiro
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2016) 15 (7): 1669–1681.
https://doi.org/10.1158/1535-7163.MCT-15-0182
Published: 05 July 2016
View article titled, PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer
Open the PDF for PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Target Identification in Small Cell Lung Cancer via Integrated Phenotypic Screening and Activity-Based Protein Profiling

Jiannong Li, Bin Fang, Fumi Kinose, Yun Bai, Jae-Young Kim, Yian A. Chen, Uwe Rix, John M. Koomen, Eric B. Haura
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2016) 15 (2): 334–342.
https://doi.org/10.1158/1535-7163.MCT-15-0444
Published: 07 February 2016
View article titled, Target Identification in Small Cell Lung Cancer via Integrated Phenotypic Screening and Activity-Based Protein Profiling
Open the PDF for Target Identification in Small Cell Lung Cancer via Integrated Phenotypic Screening and Activity-Based Protein Profiling in another window
Includes: Supplementary data
Journal Articles

Abstract A71: Differential proteome-wide target profiles of clinical poly(ADP-ribose) polymerase inhibitors in breast cancer

Claire Knezevic, Gabriela Wright, Brent Kuenzi, Lily Remsing Rix, Yunting Luo, Harshani Lawrence, Uwe Rix
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): A71.
https://doi.org/10.1158/1535-7163.TARG-15-A71
Published: 01 December 2015
View article titled, Abstract A71: Differential proteome-wide target profiles of clinical poly(ADP-ribose) polymerase inhibitors in breast cancer
Journal Articles

Identification of Kinase Inhibitor Targets in the Lung Cancer Microenvironment by Chemical and Phosphoproteomics

Manuela Gridling, Scott B. Ficarro, Florian P. Breitwieser, Lanxi Song, Katja Parapatics, Jacques Colinge, Eric B. Haura, Jarrod A. Marto, Giulio Superti-Furga, Keiryn L. Bennett, Uwe Rix
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2014) 13 (11): 2751–2762.
https://doi.org/10.1158/1535-7163.MCT-14-0152
Published: 03 November 2014
View article titled, Identification of Kinase Inhibitor Targets in the Lung Cancer Microenvironment by Chemical and Phosphoproteomics
Open the PDF for Identification of Kinase Inhibitor Targets in the Lung Cancer Microenvironment by Chemical and Phosphoproteomics in another window
Includes: Supplementary data
Journal Articles

An Integrated Chemical Biology Approach Identifies Specific Vulnerability of Ewing's Sarcoma to Combined Inhibition of Aurora Kinases A and B

Georg E. Winter, Uwe Rix, Andrej Lissat, Alexey Stukalov, Markus K. Müllner, Keiryn L. Bennett, Jacques Colinge, Sebastian M. Nijman, Stefan Kubicek, Heinrich Kovar, Udo Kontny, Giulio Superti-Furga
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (10): 1846–1856.
https://doi.org/10.1158/1535-7163.MCT-11-0100
Published: 09 October 2011
View article titled, An Integrated Chemical Biology Approach Identifies Specific Vulnerability of Ewing's Sarcoma to Combined Inhibition of Aurora Kinases A and B
Open the PDF for An Integrated Chemical Biology Approach Identifies Specific Vulnerability of Ewing's Sarcoma to Combined Inhibition of Aurora Kinases A and B in another window
Includes: Supplementary data